Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A00778-45 | Registry Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Innate Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented.
This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lung cancer |
| ||
| Central Nervous System Cancers |
| ||
| Head and Neck and upper aero-digestive tract cancers |
| ||
| Skin cancers |
| ||
| Sarcomas |
| ||
| Urothelial cancer |
| ||
| Hepatocarcinoma |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| immunohistochemistry assay | Other | biomarkers expression |
|
| Measure | Description | Time Frame |
|---|---|---|
| Immunohistochemistry scores | The immunohistochemistry scores is evaluated with the score of the percentage of stained cells. Scale of the score of the percentage of stained cells, From 0 to 4, 0 : no stained cell (absence)
| 24 months |
| Immunohistochemistry scores | The immunohistochemistry scores is evaluated with the score of the staining intensity. Staining Intensity: from 0 to 3 0 : no staining (absence)
| 24 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with solid cancer
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| BARLESI Fabrice, PU-PH | Contact | 491385590 | +33 | fabrice.barlesi@ap-hm.fr |
| Name | Affiliation | Role |
|---|---|---|
| ARNAUD Jean-Olivier, Director | Assistance Publique Hôpitaux de Marseille | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille | Recruiting | Marseille | 13354 | France |
Not provided
Not provided
Not provided
Not provided
Samples in formalin-fixed paraffin-embedded material block